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The aim of this study was to investigate human erythrocytes as a carrier for targeted drug
delivery of primaquine (PQ). The process of PQ loading in human erythrocytes, as well as the
effect of PQ loading on the oxidative status of erythrocytes, was also studied. At PQ concen-
trations of 2, 4, 6, and 8 mg/mL and an incubation time of 2 h, the ratios of the concentrations
of PQ entrapped in erythrocytes to that in the incubation medium were 0.515, 0.688, 0.697
and 0.788, respectively. The maximal decline of erythrocyte reduced glutathione content was
observed at 8 mg/mL of PQ compared with native erythrocytes p < 0.001. In contrast, malon-
dialdehyde and protein carbonyl were significantly increased in cells loaded with PQ
(p < 0.001). Furthermore, osmotic fragility of PQ carrier erythrocytes was increased in com-
parison with unloaded cells. Electron microscopy revealed spherocyte formation with PQ car-
rier erythrocytes. PQ-loaded cells showed sustained drug release over a 48 h period.
Erythrocytes were loaded with PQ successfully, but there were some biochemical as well as
physiological changes that resulted from the effect of PQ on the oxidative status of drug-
loaded erythrocytes. These changes may result in favorable targeting of PQ-loaded cells to
reticulo-endothelial organs. The relative impact of these changes remains to be explored in
ongoing animal studies. 
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INTRODUCTION
Primaquine (PQ), an 8-aminoquinoline, is widely
used for the treatment of malarial infection, but its
therapeutic use has been limited because of its side
effects, such as gastrointestinal disturbances, granulo-
cytopenia and hemolytic anemia (Kaur et al., 2010). In
addition, PQ has a short plasma half-life, necessitating
frequent administration, which then aggravates its
adverse effects. Moreover, its adverse effects are
enhanced because the drug must be frequently
administered at high doses, due to its limited oral
bioavailability (Vale et al., 2009). To reduce PQ side
effects and increase its therapeutic efficacy, several
studies have suggested different formulations for PQ
administration such as transdermal systems (Mayorga
et al., 1997), nanoparticles (Bhadra et al., 2005), micro-
particles (Nishi and Jayakrishnan, 2004), and PQ-
loaded erythrocytes (Talwar and Jain, 1992). Pharma-
cokinetic studies revealed that these formulations
achieved sustained release (Vale et al., 2009), dose
reduction (Rodrigues et al., 1995), improved stability
(Stensrud et al., 2000; Singh and Vingkar, 2008), and
enhanced liver delivery (Dierling and Cui, 2005) when
compared to that of free PQ administration.
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Erythrocytes are preferred as a drug delivery
system because they are biocompatible and bio-
degradable, have a long half-life, and can be loaded
with a variety of drugs (Patel et al., 2008). Anticancer,
antiviral, and antiparasitic drugs are examples of
therapeutic agents that have been loaded into
erythrocytes (Gutiérrez Millán et al., 2004). Erythrocytes
were used either as a carrier for sustained release of
the drugs or to accomplish targeted delivery of the
drugs to infected organs (Jaitely et al., 1996; Hamidi
et al., 2007a).
The safety and utilization of erythrocytes as carrier
systems have been previously discussed (Adams et al.,
2003). The major problem encountered in the use of
biodegradable natural cells as drug carriers is that
they are removed in vivo by the reticuloendothelial
system (RES) as a result of modifications that occur
during the loading procedure in cells. Although this
expands the capability of erythrocytes to target the
RES, it seriously limits their life-span as long-
circulating drug carriers in circulation and, in some
cases, may pose toxicological problems (Hamidi et al.,
2007a; Patel et al., 2008).
Utilization of erythrocytes as a drug carrier in
humans also has the inherited problems of transfusion
of blood from one to another, possible contamination
due to the origin of the blood, the equipment used, and
the loading environment (Adams et al., 2003).
Therefore, screenings of these carriers for the absence
of diseases as well as rigorous controls are required
for the collection and handling of erythrocytes to
eliminate any risk of contamination (Jain and Jain,
1997; Valbonesi et al., 2001).
Also, erythrocytes as a drug carrier raises other
potential concerns due to the changes in their
biochemical nature.
Drugs or other bioactive agents can be loaded in
erythrocytes either by physical methods (e.g., an
electrical pulse method or osmosis-based systems) or
by chemical methods (e.g., chemical perturbation of
the erythrocyte membrane) (Gopal et al., 2007). For
successful entrapment into the erythrocytes, the drug
should have a degree of water solubility and resistance
to degradation within erythrocytes (Hamidi et al.,
2007b). Certain drugs have been entrapped in
erythrocytes by endocytosis, including vinblastine,
chlorpromazine, hydrocortisone, propranolol, tetracaine,
retinol, and PQ (Gopal et al., 2007).
Many drugs and chemicals are able to react with
membrane lipids and proteins through crosslinking or
oxidation, which may alter the asymmetry of the
erythrocyte membrane. PQ, for example, may expose
erythrocytes to excess oxidative stress, leading to
depletion of the major antioxidant (reduced glutathione,
GSH) and an increase in membrane lipid peroxidation
and liberation of malondialdehyde (MDA) as a pero-
xidation product (Becker et al., 2004). Oxidative
injury to erythrocytes leads to membrane asymmetry,
which increases the possibility of erythrocyte uptake
by macrophages, and therefore accelerates their elimi-
nation from the circulation by the RES (Zwaal and
Schroit, 1997). An increase in the amount of oxidatively
modified proteins is a hallmark of the ageing of
erythrocytes (Robaszkiewicz et al., 2008). In the
present study, the effect of PQ concentration and
incubation time on the efficiency of PQ loading into
human erythrocytes were determined. Furthermore,
PQ-induced oxidative stress on  erythrocytes was de-
monstrated by determination of GSH and MDA,
whereas erythrocyte protein carbonyl content was
measured as an indicator of protein oxidation. Also,
the osmotic fragility of both native and PQ-loaded
erythrocytes was determined to investigate the
physiological state of erythrocyte membranes.
MATERIALS AND METHODS
Materials
Primaquine diphosphate, adenosine triphosphate,
Ellman’s reagent [5,5-dithio-bis(2-nitrobenzoic acid)],
thiobarbituric acid, 1,1,3,3-tetraethoxypropane and
GSH were purchased from Sigma-Aldrich Chemical
Company; glutaraldehyde and HPLC grade acetonitrile
and methanol were acquired from Merck & Co., Inc.
(Whitehouse Station). All other chemicals used were
of analytical grade.
Instrumentation 
In these investigations we used the following
instruments: a Coulter® LH 780 hematology analyzer
(Beckman Coulter, Inc.); a Spectro UV-Vis Split Beam
PC, model UVS-2800 (Labomed, Inc.); a high perfor-
mance liquid chromatography system consisting of a
Waters 1525 binary pump, a Waters 717 Plus auto-
sampler, a Waters 2487 dual wavelength absorbance
detector (Waters Inc.), a Nucleodur® C18 Gravity
column (5 µm, 4.6 × 250 mm) (Macherey-Nagel GmbH
& Co. KG); and a CT5 centrifuge.
Blood collection and preparation
This study was approved by the research center
ethics committee of King Saud University, College of
Pharmacy, Riyadh, Saudi Arabia and informed consent
was obtained from each of the blood donors. The blood
samples were used immediately after collection. They
were collected in heparinized vacutainers from
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healthy individual blood donors and centrifuged for 5
min at 5000 rpm. The plasma and the buffy coat were
removed by aspiration. The erythrocytes were washed
three times in cold phosphate buffered saline (PBS)
with centrifugation for 5 min at 5000 rpm (Hamidi
et al., 2007b).
PQ loading procedures
Erythrocyte suspensions with hematocrits adjusted
to 40% were incubated with different concentrations
of PQ (2, 4, 6, or 8 mg/mL) in PBS for 2 h at 37°C with
mild agitation. Five hundred µL aliquots were taken
at 30, 60, and 120 min, immediately centrifuged at
5000 rpm for 5 min, and used for extraction and
quantification of PQ (Talwar and Jain, 1992).
Erythrocyte counts
Normal, PBS-suspended, and PQ-loaded erythrocytes
were counted. The mean corpuscular volume (MCV),
the mean corpuscular hemoglobin (MCH), and the
mean corpuscular hemoglobin concentration (MCHC)
were measured using a Coulter® LH 780 hematology
analyzer.
Scanning electron microscopy (SEM)
A JEOL JSM-6380 LA scanning electron microscope
(Jeol Ltd.) equipped with a digital camera, at a 20 kV
accelerating voltage was used to evaluate mor-
phological differences between normal and PQ-
loaded erythrocytes. Both normal and 8 mg/mL PQ-
loaded erythrocyte samples were processed as follows.
After the samples were fixed in buffered glutaralde-
hyde, the aldehyde medium was drained off. The cells
were rinsed 3 times for 5 min in phosphate buffer and
post-fixed in osmium tetroxide for 1 h. The samples
were then rinsed with distilled water and dehydrated
using a graded ethanol series: 25, 50, 75, 100, and
another 100%, each for 10 min. The samples were
rinsed in water, removed, mounted on studs, sputter-
coated with gold, and then viewed using SEM (Hamidi
et al., 2007b).
Determination of osmotic fragility
A 25 µL erythrocyte sample was added to each of a
series of 2.5 mL saline solutions containing 0.0 to 0.9
g % NaCl. After gentle mixing and standing for 15
min at room temperature, the erythrocyte suspensions
were centrifuged at 5000 rpm for 5 min. The ab-
sorbance of the supernatant was measured at 540 nm
(Kraus et al., 1997). The released hemoglobin was
expressed as percentage absorbance of each sample in
reference to a completely lysed sample prepared by
diluting packed cells of each type with 1.5 mL of
distilled water.
In vitro release of hemoglobin and PQ from
carrier erythrocytes 
To study the in vitro release of both hemoglobin and
PQ, carrier erythrocytes were resuspended in PBS to
a final hematocrit of 30%. The suspensions were
incubated at 37°C with gentle shaking and aliquots
were removed at 0.5, 1, 2, 24, and 48 h. The aliquots
were centrifuged at 5000 rpm for 5 min and the
supernatant separated. The concentration of hemo-
globin and PQ released into the PBS was determined.
The release studies were performed in triplicate with
carrier erythrocytes prepared using 2 h of incubation
time and an initial PQ concentration of 8 mg/mL
(Talwar and Jain, 1992; Hamidi et al., 2007b;
Gutiérrez-Millán et al., 2008).
HPLC analysis of PQ
The PQ concentration was determined using a
modified version of literature HPLC techniques (Talwar
and Jain, 1992; Mayorga et al., 1997). Briefly,
erythrocytes loaded with PQ were hemolysed by adding
distilled water (1:1). The lysate was deproteinized
with methanol (1:1.5). A 200 µL sample was mixed
with 300 µL of methanol, vortexed for 30 sec, and then
centrifuged for 15 min at 13,000 rpm. The supernatant
was filtered and injected into the HPLC system. The
mobile phase consisted of 0.05% trifluoroacetic acid
and acetonitrile (75:25), with a 2 mL/min flow rate.
The absorbance was measured at 265 nm.
Determination of erythrocyte GSH content
A literature spectrophotometric assay (Ko et al.,
2008) was used for determination of GSH levels in
erythrocyte samples. The peptide was precipitated
from erythrocyte lysates by trichloroacetic acid (TCA).
The mixture was filtered and 200 µL of the filtrate
was added to 800 µL of 0.3 M phosphate buffer and
100 µL of 0.2% (w/v) Ellman’s reagent for color
development. The absorbance of the yellow color was
measured at 412 nm. The concentration of GSH was
calculated using a standard curve for GSH.
Determination of erythrocyte lipid peroxida-
tion
Lipid peroxidation was assayed by MDA mea-
surement using a published spectrophotometric method
(Ohkawa et al., 1979). A mixture of 200 µL of 8%
sodium dodecyl sulfate, 200 µL of 0.9% thiobarbituric
acid, and 1.5 mL of 20% acetic acid were added to a
200 µL red blood cell lysate sample; then 1.9 mL of
distilled water brought the volume to 4 mL. After
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boiling for 1 h, the mixture was cooled and 5 mL of an
n-butanol and pyridine (15:1) solution was added. The
mixture was centrifuged at 5000 rpm for 15 min and
the absorbance was measured at 532 nm. Quantifi-
cation of MDA levels was performed using tetraethoxy-
propane, the unstable malondialdehyde tetraethylace-
tal, as a standard.
Assessment of erythrocyte protein oxidation 
Protein carbonyl was assayed as a marker for
erythrocyte protein oxidation, according to the method
of Levine et al. (1994). Red blood cells were hemolysed,
and proteins were precipitated by the addition of 10%
TCA. The proteins were resuspended in 1.0 mL of 2 M
HCl for the blank, and 2 M HCl containing 2% 2,4-
dinitrophenyl hydrazine for test samples. After
incubation for 1 h at 37°C, protein samples were
washed with alcohol and ethyl acetate, and re-
precipitated by addition of 10% TCA. The precipitated
protein was dissolved in 6 M guanidine hydrochloride
solution and absorbance was measured at 370 nm.
Calculations were made using the molar extinction
coefficient of 22 × 103 M-1-cm-1 and the results are
expressed as nmol carbonyls formed per mg protein.
Total protein in the red blood cell (RBC) pellet was
assayed according to the method of Lowry et al. (1951)
using bovine serum albumin as the standard.
Statistical analysis
The significance of the differences between native
and loaded erythrocytes were analyzed by one way
ANOVA followed by the Tukey Kramer multiple
comparison test, using GraphPad® Prism Software, v.
5.01 (GraphPad Software, Inc.). Results with p < 0.05
were considered statistically significant.
RESULTS AND DISCUSSION
Our intent was to use loaded erythrocytes as a drug
delivery system to target delivery of PQ to the RES, in
particular the liver and spleen. An elevated loading of
PQ into erythrocytes was associated with a higher
concentration of PQ in the incubation medium, in the
2 - 8 mg/mL concentration range (Table I). The highest
level of loaded PQ was attained using 8 mg/mL of PQ
with a 2 h incubation time.
Studies have shown that PQ can be loaded into
erythrocytes by an endocytotic mechanism (Gopal et al.,
2007; Hamidi et al., 2007a). Talwar and Jain (1992)
characterized and evaluated the use of rat erythrocytes
as carriers for PQ. In our study, we evaluated the
extent of loading over time and studied the effect of
PQ loading on biochemical changes in human
erythrocytes. 
Endocytosis can be increased by certain conditions
or the presence of certain factors, such as hypotonicity,
EDTA, trypsin, and an energy source (Schrier et al.,
1986). Erythrocyte energetics and calcium ions provide
an opportunity for membrane invagination and fusion
with formation of endocytotic vacuoles (Schrier et al.,
1978). PQ-induced endocytosis is dependent on the
persistence of erythrocyte energy sources (Matovcik
et al., 1985). Our findings are in agreement with an
earlier report that PQ loading is dependent on the
concentration of drug in the surrounding media
(Matovcik et al., 1985). Also, scanning of loaded
erythrocytes using electron microscopy revealed the
presence of pinocytotic vacuoles (Matovcik et al., 1985).
Persistence of endocytotic vacuoles provides con-
firmation of entrapment of PQ. Matovcik et al. (1985)
reported that membrane internalization associated
with vacuole formation can be induced in intact human
erythrocytes by incubating them with membrane
active agents. Stomatocytosis and increased calcium
membrane association can be produced by endocytosis-
inducing drugs. A drug-induced increase in calcium
membrane association may be a consequence of
stomatocytosis and may secondarily be related to
subsequent endocytosis. Moreover, PQ endocytosis is
dependent on active metabolism manifested by a
requirement for an energy source (Schrier et al.,
1980).
Hematological parameters, such as MCV, MCH, and
MCHC, were characterized. These parameters de-
termine the influence of the encapsulation process on
the hematological properties of the erythrocytes
Table I. Concentrations of loaded primaquine (mg/mL) in
human carrier erythrocytes as a function of endocytosis
time (min) and initial PQ concentration
Loading 
time
Initial PQ
concentration Loaded PQ
30
2 0.57 ± 0.07
4 1.60 ± 0.12
6 2.70 ± 0.13
8 4.30 ± 0.03
60
2 0.67 ± 0.05
4 2.00 ± 0.05
6 3.18 ± 0.12
8 4.99 ± 0.22
120
2 1.03 ± 0.19
4 2.75 ± 0.07
6 4.18 ± 0.27
8 6.30 ± 0.27
Data are expressed as mean ± S.E.M. (n = 6). 
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(Gutiérrez-Millán et al., 2008). Table II presents the
mean hematological parameters of the PQ-loaded
erythrocytes obtained with different PQ concentrations
and values for the same cells before the loading
procedures (the control cells). A trend toward increasing
MCV with an increase in the PQ concentration is
evident, and one way ANOVA revealed that, compared
with unloaded erythrocytes, the 8 mg/mL PQ-loaded
cells have a significantly increased MCV (p < 0.001).
This indicates that, in general, loaded RBCs will be
larger in size than native cells, and this can be
attributed to internalization of PQ from the sur-
rounding medium. The MCH of loaded cells was lower
than that of native cells by about 7.85% at the same
PQ level, which could be due to hemoglobin leakage
from loaded erythrocytes. There is a significant
reduction of MCHC compared with native erythrocytes
(p < 0.001). These results indicate that the loading
procedure induced significant changes in the MCV in
comparison with native cells, which implies retention
of in vitro hematologic behaviors for PQ-loaded
erythrocytes.
GSH is the main antioxidant in erythrocytes that
protects proteins and lipids from oxidative damage.
The oxidation of such molecules can result in loss of
membrane integrity. Furthermore, GSH maintains
sulfhydryl groups of proteins in the reduced state
(Jain, 1984). Accordingly, it is relevant to investigate
the susceptibility of erythrocytes to PQ-induced oxi-
dative damage. In comparison to native erythrocytes,
PQ-loading induced a significant reduction in
erythrocyte GSH content (Fig. 1).
A significant elevation of MDA content for
erythrocytes loaded with PQ in relation to unloaded
erythrocytes was also found (Fig. 2). An increase in
the incubation time resulted in augmentation of the
MDA level and a GSH concentration decline (Fig. 3).
These results are clear indicators of enhanced oxidative
stress due to the presence of PQ. 
Erythrocyte membrane lipids are the most important
targets of intracellular peroxidation, resulting in cell
membrane damage (Jain, 1984). The presence of a
high content of polyunsaturated fatty acids makes
them more sensitive to oxidative injury (Chiu et al,
Table II. Hematological parameters of control erythrocytes and loaded erythrocytes obtained with different
concentrations of PQ (mg/mL)
Parameters
Initial concentration of PQ 
Control 2 4 6 8
MCV (fl) 84.8 ± 0.92 84.2 ± 1.07 88.4 ± 0.87 89.7 ± 1.23 97.5 ± 2.19***
MCH (pg) 29.3 ± 0.49 28.0 ± 0.69 29.4 ± 0.44 28.6 ± 0.72 27.0 ± 0.48*
MCHC (g/dL) 33.7 ± 0.53 32.8 ± 0.34 33.5 ± 0.20 32.8 ± 0.22 30.7 ± 0.88***
MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; fl,
femtoliters. Data are expressed as mean ± S.E.M. (n = 6). *Significantly different at p < 0.05; ***Significantly different at p < 0.001
compared to unloaded erythrocytes (control).
Fig. 1. Effect of different PQ (mg/mL) concentrations on
erythrocyte glutathione content after 2 h incubation time.
Data are expressed as mean ± S.E.M. (n = 5). *Significantly
different at p < 0.05; **Significantly different at p < 0.01;
***Significantly different at p < 0.001, compared to unloaded
erythrocytes (0 concentration).
Fig. 2. Effect of different PQ (mg/mL) concentrations on
erythrocyte malondialdehyde content after a 2 h incubation.
Data are expressed as mean ± S.E.M. (n = 6). *Significantly
different at p < 0.05; **Significantly different at p < 0.01;
***Significantly different at p < 0.001, compared to unloaded
erythrocytes (0 concentration).
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1989). Mandal et al. (2002) reported that treatment of
human erythrocytes with drugs induces oxidative
modification that accelerates their clearance from the
blood. This oxidative stress alters the asymmetry
within the erythrocyte membrane, and rapid elimi-
nation of oxidized erythrocytes from the circulation is
accelerated by alteration of the asymmetry (Jain,
1984). Another report stated that oxidatively modified
erythrocytes are flagged for phagocytosis (Tyurina
et al., 2000). 
One of the functions of erythrocyte membrane
proteins is the maintenance of aminophospholipids on
the inner leaflet of the lipid bilayer. Moreover,
membrane-bound proteinases serve as an antioxidant
defense by removal of the oxidatively altered proteins
(Beppu et al., 1994). The oxidative modification of
proteins may be one of the factors responsible for the
altered membrane asymmetry of oxidized RBC mem-
branes (Dumaswala et al., 1997). Oxidative stress can
induce denaturation of proteins through an increase
in the formation of disulfide bonds and carbonyl
groups (Rodrigues et al., 1995).
In the present work, we estimated protein carbonyl
formation to assess PQ-mediated protein oxidation of
loaded erythrocytes. We found a significant elevation
of protein carbonyl (PCO) content of erythrocytes loaded
with PQ after 2 h exposure to 6 and 8 mg/mL PQ (Fig.
4). These results are in agreement with a previous
report that exposure of erythrocytes to chemicals
increases membrane protein oxidation (Pandey et al.,
2009). Dumaswala et al. (1997) reported that an-
tioxidant membrane-bound proteinases are lost due to
oxidative modification. Therefore, PQ-induced oxidation
of protein, as indicated by an increase in PCO, is similar
to effects reported under conditions of oxidation
(Bukowska et al., 2008). It has also been reported that
the increase in protein oxidation is due to oxidation of
thiol groups and their subsequent formation of
disulfide bonds (Robaszkiewicz et al., 2008). Thus, the
induction of oxidative stress in carrier erythrocytes by
PQ, either by decreasing the GSH content or by
increasing lipid and protein oxidation, clearly occurs.
Osmotic fragility determines the susceptibility of
erythrocytes to osmotic lysis (Vettore et al., 1984). Our
investigation revealed that there is a significant
increase in the osmotic fragility of loaded erythrocyte
at 8 mg/mL PQ compared to unloaded erythrocytes
(Table III). Our results are in agreement with those of
Hamidi et al. (2001) who found that osmotic fragility
of drug-loaded erythrocytes is increased compared
with unloaded cells. Furthermore, another study
found that osmotic fragility of carrier erythrocytes is
higher than unloaded erythrocytes (Jain et al., 1997).
The low resistance of loaded cells to osmotic changes
Fig. 3. Effect of PQ (8 mg/mL) on erythrocyte glutathione and
malondialdehyde content as a function of incubation time.
Data are expressed as mean ± S.E.M. (n = 6). 
Fig. 4. Effect of different PQ (mg/mL) concentrations on
erythrocyte protein carbonyl content after a 2 h incubation.
Data are expressed as mean ± S.E.M. (n = 6). **Significantly
different at p < 0.01; ***Significantly different at p < 0.001
compared to unloaded erythrocytes (0 concentration).
Table III. Erythrocyte osmotic fragility of unloaded
erythrocytes and erythrocytes loaded with PQ (8 mg/mL).
Values are percent hemolysis in corresponding salt con-
centrations
NaCl
(%)
Unloaded 
erythrocytes
(%)
Erythrocytes
loaded
with PQ (%)
0.1 96.8 ± 4.80 98.5 ± 5.45
0.2 89.6 ± 4.60 94.9 ± 4.58
0.3 84.4 ± 4.14 89.6 ± 3.17
0.4 74.1 ± 3.04 87.7 ± 2.47*
0.5 29.7 ± 3.42 53.4 ± 4.48*
0.6 12.3 ± 1.97 34.0 ± 3.53**
0.7 7.35 ± 1.34 21.4 ± 2.39*
0.8 3.02 ± 0.66 12.4 ± 1.73*
0.9 0.95 ± 0.32 2.76 ± 0.42
Data are expressed as mean ± S.E.M. (n = 6). **Significant
at p < 0.001; *Significant at p < 0.01 compared to unloaded
erythrocytes (control).
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may be due to the loss of erythrocyte membrane
integrity. This may be caused by PQ-induced oxidative
stress of erythrocyte membrane lipids and protein. 
The main morphological change in PQ-loaded cells,
as revealed by scanning electron microscopy, was the
transformation of loaded cells from biconcave (normal)
to near spherocytes, as illustrated in Fig. 5. The
greatest change was observed with erythrocytes
loaded with 8 mg/mL PQ. Attainment of a spherical
shape due to drug loading makes the erythrocytes
more fragile. The fragile cells may be destroyed and
rapidly cleared from the circulation by macrophages
(Talwar and Jain, 1992). Further studies are required
to elucidate and demonstrate erythrophagocytosis of
PQ-loaded erythrocytes.
Additionally, results from the present study de-
monstrated that carrier erythrocytes can be used as a
sustained release delivery system for PQ. Erythrocytes
exposed to 8 mg/mL PQ for 2 h were chosen for the in
vitro release studies. Table IV presents the release
pattern for PQ and hemoglobin from loaded ery-
throcytes to PBS over a 48 h period. Following an
initial burst release over the first 2 h, the rate of
release was reasonably consistent, although the drug
release rate was 30% higher than that of hemoglobin.
During the first 2 h period, about 55% of PQ was
released from loaded cells to PBS, but only 10% of the
hemoglobin. The drug apparently diffused readily
since cell membrane lysis was not essential for release
of PQ from loaded erythrocytes. The factors that
determine drug release from carrier erythrocytes are
size and the ionization of the drug molecule (Eichler
et al., 1985). PQ diffused through the lipid bilayer to
PBS, as shown with lipophilic drugs (Lewis and Alpar,
1984).
PQ entrapment by erythrocyte endocytosis provides
a good yield when the loading medium is 8 mg/mL PQ.
As a result of the PQ loading process, the erythrocyte
GSH level is decreased, making membrane lipids and
proteins more susceptible to oxidative modifications,
as demonstrated by an increase in the MDA and PCO
content. There is a change in erythrocyte morphology
attributable to PQ loading. PQ-loaded cells exhibit
sustained release of PQ over a period of 48 h. 
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